ArticleFrontiers in pain research (Lausanne, Switzerland)2026
Low-dose esketamine for postoperative pain, sleep, and hemodynamic stability in functional endoscopic sinus surgery: a retrospective cohort study.
Article in Frontiers in pain research (Lausanne, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To evaluate the efficacy and safety of low-dose esketamine (0.2 mg/kg or 0.3 mg/kg) in improving postoperative pain, sleep quality, hemodynamic stability, and emotional status in functional endoscopic sinus surgery (FESS) patients. Methods: This retrospective cohort study analysed 135 chronic rhinosinusitis patients (January 2021-December 2023) divided into control (normal saline, Results: After PSM, 40 patients/group were analysed. The 0.3 mg/kg (5.82 ± 1.89) and 0.2 mg/kg (6.53 ± 1.59) groups had significantly lower 24-hour VAS scores than the control group did (7.16 ± 0.93, Conclusion: The use of low-dose esketamine (particularly 0.3 mg/kg) in FESS patients is associated with clinically meaningful improvements in pain control, sleep quality, emotional well-being, and hemodynamic parameters, alongside a favorable safety profile with no increase in neuropsychiatric adverse events. These findings support its consideration as a viable non-opioid analgesic adjunct in this surgical setting.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.